English

China Biologic Products, Inc.

EDGAR

CBPO Report (type unavailable) · filed 2021-04-20

118 filing records in this dataset, filed from 2007-11-15 to 2021-04-20. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

89.3 million USD

2017 Q2 · USD

Exact inputs and evidence

Revenue: 89277897 USD Source

Operating margin

44.13%

2017 Q2 · %

Exact inputs and evidence

Operating Income: 39400879 USD Source
Revenue: 89277897 USD Source

Operating cash flow

23.9 million USD

2017 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 36896460 USD Source
Operating Cash Flow: 13033027 USD Source

Free cash flow

16.8 million USD

2017 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 36896460 USD Source
Operating Cash Flow: 13033027 USD Source
Capital Expenditure: 15975643 USD Source
Capital Expenditure: 8936981 USD Source

Cash and cash equivalents: 162 million Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 2019-12-31 Source
Exact value

161750425 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg
Long-term debt including current maturities: 0 USD 2015-12-31 Source
Exact value

0 USD
Shares outstanding: 38.5 million Unit_Standard_shares_yb1rqwmGyUO_sKEP_2fqSQ 2019-12-31 Source
Exact value

38459769 Unit_Standard_shares_yb1rqwmGyUO_sKEP_2fqSQ

Reported share-count change

-2.29% · -902 thousand Unit_Standard_shares_yb1rqwmGyUO_sKEP_2fqSQ

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

39361616 Unit_Standard_shares_yb1rqwmGyUO_sKEP_2fqSQ · 2018-12-31· Source
38459769 Unit_Standard_shares_yb1rqwmGyUO_sKEP_2fqSQ · 2019-12-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

345 million USD

2016-07-01 – 2017-06-30

Exact inputs and evidence

Revenue: 86525885 USD · 2016-07-01 – 2016-09-30 Source
Revenue: 341169426 USD · 2016-01-01 – 2016-12-31 Source
Revenue: 263534751 USD · 2016-01-01 – 2016-09-30 Source
Revenue: 91453112 USD · 2017-01-01 – 2017-03-31 Source
Revenue: 89277897 USD · 2017-04-01 – 2017-06-30 Source

Net income

109 million USD

2016-07-01 – 2017-06-30

Exact inputs and evidence

Net income: 28391361 USD · 2016-07-01 – 2016-09-30 Source
Net income: 104779307 USD · 2016-01-01 – 2016-12-31 Source
Net income: 85341651 USD · 2016-01-01 – 2016-09-30 Source
Net income: 29991849 USD · 2017-01-01 – 2017-03-31 Source
Net income: 31030484 USD · 2017-04-01 – 2017-06-30 Source

Operating cash flow

103 million USD

2016-07-01 – 2017-06-30

Exact inputs and evidence

Operating cash flow: 87316726 USD · 2016-01-01 – 2016-09-30 Source
Operating cash flow: 57012818 USD · 2016-01-01 – 2016-06-30 Source
Operating cash flow: 123258611 USD · 2016-01-01 – 2016-12-31 Source
Operating cash flow: 87316726 USD · 2016-01-01 – 2016-09-30 Source
Operating cash flow: 13033027 USD · 2017-01-01 – 2017-03-31 Source
Operating cash flow: 36896460 USD · 2017-01-01 – 2017-06-30 Source
Operating cash flow: 13033027 USD · 2017-01-01 – 2017-03-31 Source

Capital expenditure

40.1 million USD

2016-07-01 – 2017-06-30

Exact inputs and evidence

Capital expenditure: 40955964 USD · 2016-01-01 – 2016-09-30 Source
Capital expenditure: 25222545 USD · 2016-01-01 – 2016-06-30 Source
Capital expenditure: 49371318 USD · 2016-01-01 – 2016-12-31 Source
Capital expenditure: 40955964 USD · 2016-01-01 – 2016-09-30 Source
Capital expenditure: 8936981 USD · 2017-01-01 – 2017-03-31 Source
Capital expenditure: 15975643 USD · 2017-01-01 – 2017-06-30 Source
Capital expenditure: 8936981 USD · 2017-01-01 – 2017-03-31 Source

Free cash flow

63 million USD

2016-07-01 – 2017-06-30

Exact inputs and evidence

Operating cash flow: 87316726 USD · 2016-01-01 – 2016-09-30 Source
Operating cash flow: 57012818 USD · 2016-01-01 – 2016-06-30 Source
Operating cash flow: 123258611 USD · 2016-01-01 – 2016-12-31 Source
Operating cash flow: 87316726 USD · 2016-01-01 – 2016-09-30 Source
Operating cash flow: 13033027 USD · 2017-01-01 – 2017-03-31 Source
Operating cash flow: 36896460 USD · 2017-01-01 – 2017-06-30 Source
Operating cash flow: 13033027 USD · 2017-01-01 – 2017-03-31 Source
Capital expenditure: 40955964 USD · 2016-01-01 – 2016-09-30 Source
Capital expenditure: 25222545 USD · 2016-01-01 – 2016-06-30 Source
Capital expenditure: 49371318 USD · 2016-01-01 – 2016-12-31 Source
Capital expenditure: 40955964 USD · 2016-01-01 – 2016-09-30 Source
Capital expenditure: 8936981 USD · 2017-01-01 – 2017-03-31 Source
Capital expenditure: 15975643 USD · 2017-01-01 – 2017-06-30 Source
Capital expenditure: 8936981 USD · 2017-01-01 – 2017-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2021-04-20.

Financial data available through: 2019-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2019-12-31
Operating income: 3 of 11 periods available· newest 2019-12-31
Net income: 3 of 11 periods available· newest 2019-12-31
Operating cash flow: 3 of 11 periods available· newest 2019-12-31
Capital expenditure: 3 of 11 periods available· newest 2019-12-31
Total assets: 2 of 11 periods available· newest 2019-12-31
Total liabilities: 2 of 11 periods available· newest 2019-12-31
Current assets: 2 of 11 periods available· newest 2019-12-31
Current liabilities: 2 of 11 periods available· newest 2019-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2019-12-31
Long-term debt including current maturities: 3 of 11 periods available· newest 2015-12-31
Shares outstanding: 2 of 11 periods available· newest 2019-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+7.9%

Prior period

Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 466.88 million

2018-01-01 – 2018-12-31
Current period

Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 503.74 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

503744922 − 466877569 = 36867353 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg

466877569 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
503744922 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · China Biologic Products, Inc. · 2019-12-31 China Biologic Products, Inc. (edgar:1369868) Year-over-year change in Revenue: 36867353 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Concept: fundies:Revenue Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:24:51Z Snapshot: b52865f7c57ac41b73c4ef0f4f0da21890b143c053c00d858fe1d6d0351ac608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1369868?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 503744922 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#3256040 Filing: 000110465920032518 Input fundies:Revenue: 466877569 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#3295884 Filing: 000110465920032518
The citation records this snapshot. The page link may show a newer release later.
Net income
+8.4%

Prior period

Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 128.06 million

2018-01-01 – 2018-12-31
Current period

Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 138.81 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

138807748 − 128056302 = 10751446 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg

128056302 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
138807748 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · China Biologic Products, Inc. · 2019-12-31 China Biologic Products, Inc. (edgar:1369868) Year-over-year change in Net income: 10751446 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:24:51Z Snapshot: b52865f7c57ac41b73c4ef0f4f0da21890b143c053c00d858fe1d6d0351ac608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1369868?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 138807748 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#3133322 Filing: 000110465920032518 Input fundies:NetIncome: 128056302 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#3134018 Filing: 000110465920032518
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+120.6%

Prior period

Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 103.94 million

2018-01-01 – 2018-12-31
Current period

Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 229.34 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

229342343 − 103941952 = 125400391 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg

103941952 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
229342343 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · China Biologic Products, Inc. · 2019-12-31 China Biologic Products, Inc. (edgar:1369868) Year-over-year change in Operating cash flow: 125400391 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:24:51Z Snapshot: b52865f7c57ac41b73c4ef0f4f0da21890b143c053c00d858fe1d6d0351ac608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1369868?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 229342343 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#2210236 Filing: 000110465920032518 Input fundies:OperatingCashFlow: 103941952 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#2210944 Filing: 000110465920032518
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-23.5%

Prior period

Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 31.74 million

2018-01-01 – 2018-12-31
Current period

Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 24.29 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

24287087 − 31743146 = -7456059 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg

31743146 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
24287087 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · China Biologic Products, Inc. · 2019-12-31 China Biologic Products, Inc. (edgar:1369868) Year-over-year change in Capital expenditure: -7456059 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:24:51Z Snapshot: b52865f7c57ac41b73c4ef0f4f0da21890b143c053c00d858fe1d6d0351ac608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1369868?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 24287087 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#2227077 Filing: 000110465920032518 Input fundies:CapitalExpenditure: 31743146 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#2227742 Filing: 000110465920032518
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2019 2019-01-01 – 2019-12-31

Revenue Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 503.74 million 100% of revenue
Operating costs Derived Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 340.1 million 68% of revenue
Operating income Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 163.65 million 32% of revenue
Tax, interest and other Derived Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 24.84 million 4.9% of revenue
Net income Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 138.81 million 28% of revenue

Cash

Operating cash flow Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 229.34 million 46% of revenue
Capital expenditure Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 24.29 million 4.8% of revenue
Free cash flow Derived Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 205.06 million 41% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2017 18%18%63%
2018 27%69%
2019 28%68%

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2017 2017-01-01 – 2017-12-31	370406840	234548335 Derived	135858505	67915470 Derived	67943035	64679445 Derived	Source 2017-01-01 – 2017-12-31: 370406840 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Revenue Open source 2017-01-01 – 2017-12-31: 135858505 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Operating Income Open source 2017-01-01 – 2017-12-31: 67943035 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Net Income Open source 2017-01-01 – 2017-12-31: 102183885 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 37504440 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	466877569	320704818 Derived	146172751	18116449 Derived	128056302	72198806 Derived	Source 2018-01-01 – 2018-12-31: 466877569 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Revenue Open source 2018-01-01 – 2018-12-31: 146172751 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Operating Income Open source 2018-01-01 – 2018-12-31: 128056302 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Net Income Open source 2018-01-01 – 2018-12-31: 103941952 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 31743146 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	503744922	340097039 Derived	163647883	24840135 Derived	138807748	205055256 Derived	Source 2019-01-01 – 2019-12-31: 503744922 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Revenue Open source 2019-01-01 – 2019-12-31: 163647883 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Operating Income Open source 2019-01-01 – 2019-12-31: 138807748 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Net Income Open source 2019-01-01 – 2019-12-31: 229342343 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 24287087 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Capital Expenditure Open source

Amounts are exact, in Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 503.7M 2019

Values and sources

Revenue values and source evidence
Period	Series	Value(Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg)	Source evidence
20172017-12-31	Revenue	370406840	Revenue: 370406840 Open source
20182018-12-31	Revenue	466877569	Revenue: 466877569 Open source
20192019-12-31	Revenue	503744922	Revenue: 503744922 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

7.9% 2019

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Year over year	No prior comparable period	Revenue: 370406840 Open source
20182018-12-31	Year over year	26%	Revenue: 466877569 Open source Revenue: 370406840 Open source
20192019-12-31	Year over year	7.9%	Revenue: 503744922 Open source Revenue: 466877569 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 32.5% 2019

Net margin 27.6% 2019

Free cash flow margin 40.7% 2019

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Operating margin	36.7%	Operating Income: 135858505 Open source Revenue: 370406840 Open source
20182018-12-31	Operating margin	31.3%	Operating Income: 146172751 Open source Revenue: 466877569 Open source
20192019-12-31	Operating margin	32.5%	Operating Income: 163647883 Open source Revenue: 503744922 Open source
20172017-12-31	Net margin	18.3%	Net Income: 67943035 Open source Revenue: 370406840 Open source
20182018-12-31	Net margin	27.4%	Net Income: 128056302 Open source Revenue: 466877569 Open source
20192019-12-31	Net margin	27.6%	Net Income: 138807748 Open source Revenue: 503744922 Open source
20172017-12-31	Free cash flow margin	17.5%	Revenue: 370406840 Open source Operating Cash Flow: 102183885 Open source Capital Expenditure: 37504440 Open source
20182018-12-31	Free cash flow margin	15.5%	Revenue: 466877569 Open source Operating Cash Flow: 103941952 Open source Capital Expenditure: 31743146 Open source
20192019-12-31	Free cash flow margin	40.7%	Revenue: 503744922 Open source Operating Cash Flow: 229342343 Open source Capital Expenditure: 24287087 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 229.3M 2019

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg)	Source evidence
20172017-12-31	Operating cash flow	102183885	Operating Cash Flow: 102183885 Open source
20182018-12-31	Operating cash flow	103941952	Operating Cash Flow: 103941952 Open source
20192019-12-31	Operating cash flow	229342343	Operating Cash Flow: 229342343 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 205.1M 2019

Values and sources

Free cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg)	Source evidence
20172017-12-31	Free cash flow	64679445	Operating Cash Flow: 102183885 Open source Capital Expenditure: 37504440 Open source
20182018-12-31	Free cash flow	72198806	Operating Cash Flow: 103941952 Open source Capital Expenditure: 31743146 Open source
20192019-12-31	Free cash flow	205055256	Operating Cash Flow: 229342343 Open source Capital Expenditure: 24287087 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

8.4% 2019

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2017-12-31	Liabilities / assets	Not reported	No source recorded
20182018-12-31	Liabilities / assets	8.2%	Total Liabilities: 165275517 Open source Total Assets: 2009978681 Open source
20192019-12-31	Liabilities / assets	8.4%	Total Liabilities: 163006640 Open source Total Assets: 1937858497 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

10.89× 2019

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2017-12-31	Current assets / current liabilities	Not reported	No source recorded
20182018-12-31	Current assets / current liabilities	11.09×	Current Assets: 1357187822 Open source Current Liabilities: 122348782 Open source
20192019-12-31	Current assets / current liabilities	10.89×	Current Assets: 1299725398 Open source Current Liabilities: 119308691 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2017 2017-01-01 – 2017-12-31	Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 67.94 million Exact value Exact value: 67943035 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 2017-01-01 – 2017-12-31: 67943035 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Net Income Open source Share or cite Citation for Net Income · China Biologic Products, Inc. · 2017-12-31 China Biologic Products, Inc. (edgar:1369868) Net Income: 67943035 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:24:51Z Snapshot: b52865f7c57ac41b73c4ef0f4f0da21890b143c053c00d858fe1d6d0351ac608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1369868/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg&dimensions= Input fundies:NetIncome: 67943035 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#3134714 Filing: 000110465920032518 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 102.18 million Exact value Exact value: 102183885 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 2017-01-01 – 2017-12-31: 102183885 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · China Biologic Products, Inc. · 2017-12-31 China Biologic Products, Inc. (edgar:1369868) Operating Cash Flow: 102183885 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:24:51Z Snapshot: b52865f7c57ac41b73c4ef0f4f0da21890b143c053c00d858fe1d6d0351ac608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1369868/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg&dimensions= Input fundies:OperatingCashFlow: 102183885 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#2211652 Filing: 000110465920032518 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 37.5 million Exact value Exact value: 37504440 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 2017-01-01 – 2017-12-31: 37504440 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · China Biologic Products, Inc. · 2017-12-31 China Biologic Products, Inc. (edgar:1369868) Capital Expenditure: 37504440 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:24:51Z Snapshot: b52865f7c57ac41b73c4ef0f4f0da21890b143c053c00d858fe1d6d0351ac608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1369868/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg&dimensions= Input fundies:CapitalExpenditure: 37504440 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#2228407 Filing: 000110465920032518 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 64.68 million Calculation and evidence 102183885 − 37504440 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Exact free cash flow: 64679445 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 2017-01-01 – 2017-12-31: 102183885 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 37504440 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · China Biologic Products, Inc. · 2017-12-31 China Biologic Products, Inc. (edgar:1369868) Free cash flow: 64679445 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:24:51Z Snapshot: b52865f7c57ac41b73c4ef0f4f0da21890b143c053c00d858fe1d6d0351ac608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1369868?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 102183885 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#2211652 Filing: 000110465920032518 Input fundies:CapitalExpenditure: 37504440 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#2228407 Filing: 000110465920032518 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 128.06 million Exact value Exact value: 128056302 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 2018-01-01 – 2018-12-31: 128056302 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Net Income Open source Share or cite Citation for Net Income · China Biologic Products, Inc. · 2018-12-31 China Biologic Products, Inc. (edgar:1369868) Net Income: 128056302 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:24:51Z Snapshot: b52865f7c57ac41b73c4ef0f4f0da21890b143c053c00d858fe1d6d0351ac608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1369868/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg&dimensions= Input fundies:NetIncome: 128056302 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#3134018 Filing: 000110465920032518 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 103.94 million Exact value Exact value: 103941952 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 2018-01-01 – 2018-12-31: 103941952 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · China Biologic Products, Inc. · 2018-12-31 China Biologic Products, Inc. (edgar:1369868) Operating Cash Flow: 103941952 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:24:51Z Snapshot: b52865f7c57ac41b73c4ef0f4f0da21890b143c053c00d858fe1d6d0351ac608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1369868/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg&dimensions= Input fundies:OperatingCashFlow: 103941952 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#2210944 Filing: 000110465920032518 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 31.74 million Exact value Exact value: 31743146 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 2018-01-01 – 2018-12-31: 31743146 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · China Biologic Products, Inc. · 2018-12-31 China Biologic Products, Inc. (edgar:1369868) Capital Expenditure: 31743146 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:24:51Z Snapshot: b52865f7c57ac41b73c4ef0f4f0da21890b143c053c00d858fe1d6d0351ac608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1369868/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg&dimensions= Input fundies:CapitalExpenditure: 31743146 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#2227742 Filing: 000110465920032518 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 72.2 million Calculation and evidence 103941952 − 31743146 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Exact free cash flow: 72198806 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 2018-01-01 – 2018-12-31: 103941952 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 31743146 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · China Biologic Products, Inc. · 2018-12-31 China Biologic Products, Inc. (edgar:1369868) Free cash flow: 72198806 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:24:51Z Snapshot: b52865f7c57ac41b73c4ef0f4f0da21890b143c053c00d858fe1d6d0351ac608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1369868?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 103941952 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#2210944 Filing: 000110465920032518 Input fundies:CapitalExpenditure: 31743146 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#2227742 Filing: 000110465920032518 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 138.81 million Exact value Exact value: 138807748 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 2019-01-01 – 2019-12-31: 138807748 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Net Income Open source Share or cite Citation for Net Income · China Biologic Products, Inc. · 2019-12-31 China Biologic Products, Inc. (edgar:1369868) Net Income: 138807748 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:24:51Z Snapshot: b52865f7c57ac41b73c4ef0f4f0da21890b143c053c00d858fe1d6d0351ac608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1369868/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg&dimensions= Input fundies:NetIncome: 138807748 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#3133322 Filing: 000110465920032518 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 229.34 million Exact value Exact value: 229342343 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 2019-01-01 – 2019-12-31: 229342343 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · China Biologic Products, Inc. · 2019-12-31 China Biologic Products, Inc. (edgar:1369868) Operating Cash Flow: 229342343 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:24:51Z Snapshot: b52865f7c57ac41b73c4ef0f4f0da21890b143c053c00d858fe1d6d0351ac608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1369868/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg&dimensions= Input fundies:OperatingCashFlow: 229342343 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#2210236 Filing: 000110465920032518 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 24.29 million Exact value Exact value: 24287087 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 2019-01-01 – 2019-12-31: 24287087 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · China Biologic Products, Inc. · 2019-12-31 China Biologic Products, Inc. (edgar:1369868) Capital Expenditure: 24287087 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:24:51Z Snapshot: b52865f7c57ac41b73c4ef0f4f0da21890b143c053c00d858fe1d6d0351ac608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1369868/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg&dimensions= Input fundies:CapitalExpenditure: 24287087 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#2227077 Filing: 000110465920032518 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 205.06 million Calculation and evidence 229342343 − 24287087 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Exact free cash flow: 205055256 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg 2019-01-01 – 2019-12-31: 229342343 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 24287087 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · China Biologic Products, Inc. · 2019-12-31 China Biologic Products, Inc. (edgar:1369868) Free cash flow: 205055256 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:24:51Z Snapshot: b52865f7c57ac41b73c4ef0f4f0da21890b143c053c00d858fe1d6d0351ac608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1369868?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 229342343 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#2210236 Filing: 000110465920032518 Input fundies:CapitalExpenditure: 24287087 Unit_Standard_USD_RgGqOLpfxEWOYkYoR7Udzg (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/tmb-20191231x20fc97c9f.htm#2227077 Filing: 000110465920032518 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

118 filings · 2,910 latest values · 2,910 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001369868, 1369868, CBPO, cbpo, edgar:1369868

Also known as China Biologic Products Holdings, Inc., China Biologic Products, Inc.

China Biologic Products, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2019 2019-01-01 – 2019-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation